Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

797514

registered interest
date	29/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Thyroid Gland: Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what medicines NHS England has approved for patients with thyroid conditions
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	116477
answer	answer is ministerial correction date of answer 07/12/2017 answer text <p><del class="ministerial">For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</del></p><p> </p><p><del class="ministerial">In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">NHS England is not responsible for approving medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices work and are acceptably safe. The National Institute for Health and Care Excellence makes recommendations for the National Health Service on whether medicines and other treatments represent a clinically and cost effective use of NHS resources.</ins></p><p><ins class="ministerial"><strong> </strong></ins></p><p><ins class="ministerial">A list of medicines licensed by the MHRA for the treatment of thyroid conditions is attached. The list is split into two sections because thyroid conditions can be split into either those associated with an overactive thyroid (hyperthyroidism), or an underactive thyroid (hypothyroidism). The list contains only those medicines licensed for overactive and underactive thyroid. It should be noted that not all of the medicines listed will be available on the market at any one time. </ins></p></ins></p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/12/2017 15:27:25 question first ministerially corrected 07/12/2017 18:20:31 answering member 4067 label Biography information for Steve Brine attachment 1 file name 2017 12 06 Thyroid medicines formatted.xls title List of thyroid medicines previous answer version 27995 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4478 label Biography information for Royston Smith

782158

registered interest
date	01/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Action On Smoking and Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 4 September 2017 to Question 6854, whether his Department has provided funding from non-section 64 sources to the organisation Action on Smoking and Health in the 2017-18 financial year or any of the last 10 financial years.
tabling member constituency	Kettering
tabling member printed	Mr Philip Hollobone
uin	110843
answer	answer is ministerial correction date of answer 06/11/2017 answer text <p>In the past 10 years, the Department has paid Action on Smoking and Health (ASH) a total of £16,016.40 in non-grant funding for help in implementing additional strategies targeted at tackling health inequalities.</p><p> </p><p>Grant funding has also been given to ASH as <ins class="ministerial">in the attached table </ins><del class="ministerial">follows</del>. <ins class="ministerial">Any payment to ASH in respect of activity for 2017-18 will depend upon the outcome of a competitive process to secure support for delivery of the Tobacco Control Plan. </ins>The Department’s financial records do not provide the level of detail to confirm whether funding was made under the legal power Section 64 of the Health and Public Services Act 1968 for all of this period. However, local records can confirm <ins class="ministerial">only</ins> Section 64 has been used since the financial year 2012/13.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/11/2017 17:30:52 question first ministerially corrected 08/11/2017 10:47:05 answering member 4067 label Biography information for Steve Brine attachment 1 file name Grant Funding to Action on Smoking and Health.docx title Grant Funding to ASH previous answer version 20537 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	1537 label Biography information for Mr Philip Hollobone

777814

registered interest
date	25/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which prescription drugs had the highest increase in price to the NHS in the last 10 years for which data is available.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	109619
answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>The table below shows the top five individual medicines <del class="ministerial">and chemicals</del> that have shown the highest increase in <ins class="ministerial">cost</ins> <del class="ministerial">price </del> over the last 10 years for Net Ingredient Cost (NIC) per prescription item <del class="ministerial">and NIC per quantity</del>. Prescription medicines<del class="ministerial">/chemicals</del> have only been included where there was prescribing in both 2006 and 2016.</p><p><ins class="ministerial">For any medicine listed, it does not necessarily mean that the price has increased. For example, the cost per prescription item will be higher if the quantity being prescribed per prescription item has increased.</ins></p><p>This is based on Prescription Cost Analysis (PCA) data. PCA data is based on analysis of all prescriptions dispensed in the community i.e. by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered in England. PCA data do not cover drugs dispensed in hospitals, including mental health trusts, or private prescriptions.</p><p> </p><p>Costs vary over time due to numerous factors including medicines going off patent and becoming available generically, unlicensed medicines becoming licensed medicines, shortages, the level of competition for generic medicines, as well as centrally agreed pricing schemes such as the Pharmaceutical Price Regulation Scheme.</p><p> </p><p>The Department is working closely with the Competition and Markets Authority on a number of investigations into unwarranted price rises of unbranded generic medicines. Where companies have breached competition law, we will seek damages and invest that money back into the National Health Service.</p><p> </p><table><tbody><tr><td colspan="4"><p>The top five medicines with the highest increase in Net Ingredient<sup>1</sup> Cost per prescription item<sup>2</sup></p></td></tr><tr><td><p>Drug Name</p></td><td><p>2006</p></td><td><p>2016</p></td><td><p>Increase</p></td></tr><tr><td><p>Orfadin_Cap 10mg</p></td><td><p>£5,436.74</p></td><td><p>£20,030.86</p></td><td><p>£14,594.12</p></td></tr><tr><td><p>Cerezyme_I/V Inf 400u Vl (Dry)</p></td><td><p>£18,143.17</p></td><td><p>£30,397.85</p></td><td><p>£12,254.68</p></td></tr><tr><td><p>Chenodeoxycholic Acid_Cap 250mg</p></td><td><p>£88.57</p></td><td><p>£9,580.10</p></td><td><p>£9,491.54</p></td></tr><tr><td><p>Trientine Dihydroch_Cap 300mg (Old)</p></td><td><p>£218.58</p></td><td><p>£5,488.22</p></td><td><p>£5,269.64</p></td></tr><tr><td><p>Sod Benz_Liq Spec 400mg/5ml</p></td><td><p>£361.95</p></td><td><p>£4,352.92</p></td><td><p>£3,990.96</p></td></tr></tbody></table><p>Source: Prescription Cost Analysis</p><p> </p><p>Notes:</p><p> </p><p><sup>1</sup>NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income, so the amount the NHS spent will be slightly different.</p><p> </p><p><sup>2</sup>Prescriptions are written on a prescription form known as an FP10. Each single item written on the form is counted as a prescription item.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/11/2017 14:32:18 question first ministerially corrected 12/12/2017 13:55:12 answering member 4067 label Biography information for Steve Brine previous answer version 20077 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	534 label Biography information for Chris Ruane

757686

registered interest
date	05/09/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Measles: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the immunisation rate is for measles; and what steps the Government is taking to improve measles immunisation coverage.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	8870
answer	answer is ministerial correction date of answer 13/09/2017 answer text <p>Protection against measles is provided in the combination measles, mumps and rubella vaccine (MMR).</p><p>The latest <del class="ministerial">England</del> vaccine coverage figures <ins class="ministerial">for the United Kingdom</ins> (January to March 2017) show that uptake of one dose of MMR vaccine at two years was 91.7% and at five years was 95.4%, exceeding the World Health Organisation’s elimination target. Uptake of two MMR doses at five years was 88.1%.</p><p> </p><p>In November 2016, a measles and rubella elimination strategy group was established to oversee the development of a United Kingdom-wide Measles and Rubella elimination strategy. This strategy will focus on sustaining very high coverage of MMR in children below five years of age and on providing opportunities for MMR catch-up to older population groups at risk for measles and/or rubella. Public Health England (PHE) continues to work with others to supply information for health professionals and the public on the benefits and risks associated with MMR.</p><p> </p><p>PHE and NHS England work closely with providers at a local level to target specific communities where uptake of the MMR vaccine is known to be poor.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/09/2017 15:11:29 question first ministerially corrected 15/09/2017 14:52:33 answering member 4067 label Biography information for Steve Brine previous answer version 11365 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	318 label Biography information for John Spellar

754729

registered interest
date	20/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the total number of repeat prescriptions issued by (a) high street and (b) internet pharmacies has been in each year since 2007 in (i) England and (ii) each local authority area.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	6406
answer	answer is ministerial correction date of answer 11/09/2017 answer text <p>The total number of repeat dispensing prescription items issued by wholly distance selling pharmacies, including internet pharmacies, and other community pharmacies, including those on the high street, for each year since April 2013 in England is detailed in the table below:</p><table><tbody><tr><td><p>Time Period</p></td><td><p>Repeat Dispensing Prescription Items for Distant Selling Pharmacies</p></td><td><p>Repeat Dispensing Prescription Items for Other Community Pharmacies</p></td><td><p>Yearly Total</p></td></tr><tr><td><p>2013 (Apr-Dec 2013)</p></td><td><p>625,157</p></td><td><p>49,222,450</p></td><td><p>49,847,607</p></td></tr><tr><td><p>2014 (Jan-Dec 2014)</p></td><td><p>1,076,060</p></td><td><p>73,769,909</p></td><td><p>74,845,969</p></td></tr><tr><td><p>2015 (Jan-Dec 2015)</p></td><td><p>1,482,942</p></td><td><p>84,411,853</p></td><td><p>85,894,795</p></td></tr><tr><td><p>2016 (Jan-Dec 2016)</p></td><td><p>2,001,326</p></td><td><p>95,730,820</p></td><td><p>97,732,146</p></td></tr><tr><td><p>2017 (Jan-May 2017)</p></td><td><p>930,753</p></td><td><p>42,216,958</p></td><td><p>43,147,711</p></td></tr><tr><td><p>Total</p></td><td><p>6,116,238</p></td><td><p>345,351,990</p></td><td><p>351,468,228</p></td></tr></tbody></table><p>The requested data is not provided before 2013 as the NHS Business Services Authority only holds prescription payment data for a period of 60 months, at which point it is destroyed in line with their records management policy. Also this coincides with NHS England becoming responsible for commissioning community pharmacy services from April 2013. As such, data is attached on repeat dispensing prescription items by NHS England local areas, rather than local authority areas.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2017 14:29:46 question first ministerially corrected 12/09/2017 09:25:45 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ6406 Repeats appendix FINAL.xlsx title Repeat prescriptions by NHS England area previous answer version 9595 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth